- Home
- SRFM vs CMMB Comparison
SRFM vs CMMB Comparison
Compare SRFM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 11.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SRFM | CMMB |
|---|---|---|
| Price | $1.17 | $1.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.25 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.2M | 47.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.69 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | ★ N/A | $39.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $0.87 |
| 52 Week High | $9.35 | $3.86 |
Technical Indicators
Market Signals| Indicator | SRFM | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 30.07 | 42.83 |
| Support Level | N/A | $1.48 |
| Resistance Level | $2.16 | $1.64 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 24.01 | 14.00 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.